JP2024539502A5 - - Google Patents
Info
- Publication number
- JP2024539502A5 JP2024539502A5 JP2024547821A JP2024547821A JP2024539502A5 JP 2024539502 A5 JP2024539502 A5 JP 2024539502A5 JP 2024547821 A JP2024547821 A JP 2024547821A JP 2024547821 A JP2024547821 A JP 2024547821A JP 2024539502 A5 JP2024539502 A5 JP 2024539502A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- liquid formulation
- stable liquid
- formulation according
- arginine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2115127.9A GB202115127D0 (en) | 2021-10-21 | 2021-10-21 | Formulations |
| GB2115127.9 | 2021-10-21 | ||
| PCT/EP2022/079185 WO2023067051A1 (en) | 2021-10-21 | 2022-10-20 | Formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024539502A JP2024539502A (ja) | 2024-10-28 |
| JP2024539502A5 true JP2024539502A5 (https=) | 2025-10-22 |
Family
ID=78806159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024547821A Pending JP2024539502A (ja) | 2021-10-21 | 2022-10-20 | 製剤 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20250281403A1 (https=) |
| EP (1) | EP4419077A1 (https=) |
| JP (1) | JP2024539502A (https=) |
| KR (1) | KR20240099316A (https=) |
| CN (1) | CN118175989A (https=) |
| AR (1) | AR127420A1 (https=) |
| AU (1) | AU2022369042A1 (https=) |
| CA (1) | CA3235492A1 (https=) |
| CL (1) | CL2024001232A1 (https=) |
| CO (1) | CO2024006206A2 (https=) |
| GB (1) | GB202115127D0 (https=) |
| GE (2) | GEAP202416521A (https=) |
| IL (1) | IL312211A (https=) |
| MX (1) | MX2024004873A (https=) |
| PE (1) | PE20241192A1 (https=) |
| TW (1) | TW202330029A (https=) |
| WO (1) | WO2023067051A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006100679A2 (en) | 2005-03-22 | 2006-09-28 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against human type ii transglutaminase and uses thereof |
| GB2490655A (en) | 2011-04-28 | 2012-11-14 | Univ Aston | Modulators of tissue transglutaminase |
| GB201209096D0 (en) | 2012-05-24 | 2012-07-04 | Medical Res Council Technology | Compounds |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| CN109563161A (zh) * | 2016-02-03 | 2019-04-02 | 安口生物公司 | 用于提高抗体稳定性的缓冲制剂 |
-
2021
- 2021-10-21 GB GBGB2115127.9A patent/GB202115127D0/en not_active Ceased
-
2022
- 2022-10-20 PE PE2024000907A patent/PE20241192A1/es unknown
- 2022-10-20 KR KR1020247016677A patent/KR20240099316A/ko active Pending
- 2022-10-20 EP EP22809342.3A patent/EP4419077A1/en active Pending
- 2022-10-20 WO PCT/EP2022/079185 patent/WO2023067051A1/en not_active Ceased
- 2022-10-20 IL IL312211A patent/IL312211A/en unknown
- 2022-10-20 CN CN202280070452.XA patent/CN118175989A/zh active Pending
- 2022-10-20 CA CA3235492A patent/CA3235492A1/en active Pending
- 2022-10-20 AU AU2022369042A patent/AU2022369042A1/en active Pending
- 2022-10-20 TW TW111139754A patent/TW202330029A/zh unknown
- 2022-10-20 MX MX2024004873A patent/MX2024004873A/es unknown
- 2022-10-20 JP JP2024547821A patent/JP2024539502A/ja active Pending
- 2022-10-20 US US18/703,675 patent/US20250281403A1/en active Pending
- 2022-10-20 GE GEAP202416521A patent/GEAP202416521A/en unknown
- 2022-10-20 GE GEAP202216521A patent/GEP20257801B/en unknown
- 2022-10-20 AR ARP220102860A patent/AR127420A1/es unknown
-
2024
- 2024-04-19 CL CL2024001232A patent/CL2024001232A1/es unknown
- 2024-05-16 CO CONC2024/0006206A patent/CO2024006206A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005128280A (ru) | Композиции иммуноглобулина и способ их получения | |
| JP7473603B2 (ja) | 液体医薬組成物 | |
| JP6283392B2 (ja) | 勃起不全および他の適応症の処置 | |
| AR109494A1 (es) | Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos | |
| JP2021073187A (ja) | 即効型インスリン組成物 | |
| RU2008112146A (ru) | Композиции и способы получения слаборастворимых в воде лекарственных средств с увеличенной стабильностью | |
| JP2024109816A5 (https=) | ||
| CN101272764B (zh) | hFSH水制剂 | |
| JP2022532927A5 (https=) | ||
| RU2006122638A (ru) | Фармацевтический препарат, включающий антитело против рецептора egf | |
| US4244943A (en) | Method for preparing urokinase injection | |
| JP2019536761A5 (https=) | ||
| RU2007119724A (ru) | Композиции, содержащие эктинэсайдин и дисахарид | |
| JP2024506940A5 (https=) | ||
| JP2023518066A5 (https=) | ||
| WO2022135395A1 (zh) | 稳定的抗体制剂及其制备方法和应用 | |
| JOP20220183A1 (ar) | صياغات أجسام مضادة ضد tslp بشرية وطرائق علاج مرض التهابي | |
| JP2024544415A5 (https=) | ||
| JP2024539502A5 (https=) | ||
| ES2295161T3 (es) | Solucion oftalmica. | |
| JP2024539265A5 (https=) | ||
| JP2021521168A5 (https=) | ||
| IL312211A (en) | Formulations | |
| JP2024532736A5 (https=) | ||
| RU2024113529A (ru) | Составы |